Qim­ing's Chi­na-fo­cused $1.1B new fund brings glob­al haul to $5B with­in 1 week — but the dis­tri­b­u­tion won't be even

In case you’re still won­der­ing, the glob­al ven­ture train for bio­phar­ma is def­i­nite­ly chug­ging along.

Qim­ing Ven­ture Part­ners has just closed $1.1 bil­lion for its sev­enth fund, bring­ing the grand to­tal of new biotech funds close to $5 bil­lion just over the past week. To be sure, the Chi­na-based VC al­so in­vests in medtech, di­ag­nos­tics, health­care ser­vices, in­for­ma­tion tech­nol­o­gy, ar­ti­fi­cial in­tel­li­gence, en­ter­prise ser­vices, con­sumer in­ter­net and e-com­merce — but over the past 14 years it’s es­tab­lished it­self as a pre­mier ear­ly-stage biotech backer with an eye for play­ers that even­tu­al­ly make it big.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER